Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Linical Co., Ltd.
  6. Summary
    2183   JP3974530002

LINICAL CO., LTD.

(2183)
  Report
Delayed Japan Exchange  -  11:41 2022-10-02 pm EDT
748.00 JPY   +0.81%
09/19Linical Co., Ltd.(TSE:2183) dropped from S&P Global BMI Index
CI
08/12Linical : Summary of Consolidated Financial Results for the Three Months Ended June 30, 2022 (Japanese GAAP)
PU
08/12Linical : Summary of Consolidated Financial Results for the Three Months Ended June 30, 2022 (Japanese GAAP)(321kb)
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
09/27/2022 09/28/2022 09/29/2022 09/30/2022 10/02/2022 Date
700(c) 724(c) 743(c) 742(c) 748 Last
37 900 48 600 47 700 47 800 20 000 Volume
-0.28% +3.43% +2.62% -0.13% +0.81% Change
More quotes
Estimated financial data (e)
Sales 2023 12 500 M 86,4 M 86,4 M
Net income 2023 870 M 6,01 M 6,01 M
Net cash position 2023 2 418 M 16,7 M 16,7 M
P/E ratio 2023 19,3x
Yield 2023 1,89%
Sales 2024 13 600 M 94,0 M 94,0 M
Net income 2024 1 250 M 8,64 M 8,64 M
Net cash position 2024 3 485 M 24,1 M 24,1 M
P/E ratio 2024 13,4x
Yield 2024 1,89%
Capitalization 16 759 M 116 M 116 M
EV / Sales 2023 1,15x
EV / Sales 2024 0,98x
Nbr of Employees 843
Free-Float 41,4%
More Financials
Company
Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of... 
More about the company
Ratings of Linical Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about LINICAL CO., LTD.
09/19Linical Co., Ltd.(TSE:2183) dropped from S&P Global BMI Index
CI
08/12Linical : Summary of Consolidated Financial Results for the Three Months Ended June 30, 20..
PU
08/12Linical : Summary of Consolidated Financial Results for the Three Months Ended June 30, 20..
PU
08/12Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
CI
08/12Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31,..
CI
07/15Linical : Bridge Report Financial report issued by Investment Bridge Co., Ltd.
PU
06/28Linical : (Delayed) FY 2022 Financial Results Briefing
PU
06/28Linical : (Delayed)FY 2022 Financial Results Briefing(2,410kb)
PU
05/16Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31,..
CI
05/16Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2022, Payable ..
CI
03/30LINICAL CO., LTD. : Ex-dividend day for final dividend
FA
02/14Linical : Consolidated Financial Results for the Nine Months Ended December 31, 2021 (Japa..
PU
02/14Linical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022
CI
02/14Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2021
CI
2021Linical : (Delayed) Notice and Apology regarding Possible Leakage of Personal Information,..
PU
More news
News in other languages on LINICAL CO., LTD.
08/12Linical Co., Ltd. fournit des indications sur le dividende pour l'année fiscale se term..
08/12Linical Co., Ltd. fournit des prévisions de bénéfices consolidés pour l'année se termin..
05/16Linical Co., Ltd. fournit des prévisions de bénéfices consolidés pour l'année se termin..
05/16Linical Co., Ltd. annonce le versement d'un dividende pour l'année fiscale se terminant..
02/14Linical Co., Ltd. fournit des prévisions de bénéfices pour l'année fiscale se terminant..
More news
ETFs positioned on LINICAL CO., LTD.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Nomura NEXT FUNDS TOPIX-17 IT & SERVICES, O...0.01%-1.36%-Japan
Nikko Listed Index Fund TOPIX Ex-Financials - JPY0%0.37%-Japan
Nikko Listed Index Fund TOPIX ETF - JPY0%-3.30%-Japan
Daiwa ETF TOPIX - JPY0%-3.23%-Japan
Lyxor Japan (TOPIX) (DR) - Dist - EUR0%-2.04%-Japan
More ETFs positioned on LINICAL CO., LTD.
Chart LINICAL CO., LTD.
Duration : Period :
Linical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LINICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 742,00 JPY
Average target price 1 400,00 JPY
Spread / Average Target 88,7%
EPS Revisions
Managers and Directors
Kazuhiro Hatano President & Representative Director
Akihiro Takahashi Managing Director
Shiori Yamaguchi Manager-Audit Office
Masafumi Nogimori Independent Outside Director
Akio Ohsawa Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
LINICAL CO., LTD.-4.63%116
MODERNA, INC.-53.44%46 259
LONZA GROUP AG-36.15%36 760
IQVIA HOLDINGS INC.-35.80%33 784
SEAGEN INC.-11.49%25 236
ALNYLAM PHARMACEUTICALS, INC.18.03%24 025